Common therapeutic target for both cancer and obesity

Table 1 Current status of selected type-2 methionine aminopeptidase inhibitors

Name	Type ofinhibitor	Preclinical/clinical trails
Fumagillin[7-10]	Irreversible	N/A
TNP-470[12,13]	Irreversible	Phase I
PPI-2458[49]	Irreversible	Phase I
CKD-732[61-64] (ZGN-433, beloranib)	Irreversible	Phase II/III
SDX-7320[59,60]	Irreversible	Phase II
Bengamides[65] (LAF389)	Reversible	Phase I
2-Hydroxy-3-aminoamides[66]	Reversible	Preclinical
Anthranilic acid sulfonamides[67]	Reversible	Preclinical
Triazoles[68]	Reversible	Preclinical
Indazoles[69]	Reversible	Preclinical
Pyrazolo[4,3-b]indoles[70]	Reversible	Preclinical

N/A: Not applicable.